Successful use of tocilizumab in a patient with rheumatoid arthritis following severe pancytopenia during etanercept therapy

Journal of Clinical Rheumatology

Volumn 17, Issue 7, 2011, Pages 377-379

  Szalay, Balázs ^a   Ács, Lilla ^b   Vásárhelyi, Barna ^a   Kovács, László ^b   Balog, Attila ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

apoptosis; etanercept; pancytopenia; rheumatoid arthritis; tocilizumab

Indexed keywords

ACICLOVIR; ALPHA TOCOPHEROL; CIPROFLOXACIN; ETANERCEPT; FOLIC ACID; LIPOCORTIN 5; METHOTREXATE; METHYLPREDNISOLONE; PROPIDIUM IODIDE; RETINOL; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

AGED; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; HUMAN; MOUTH ULCER; PANCYTOPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; PANCYTOPENIA; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 80053347081     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318231fd99     Document Type: Article

References (12)

1. Desai SB, Furst DE. Problems encountered during antiYtumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;4:757-790.
2. Levalampi T, Korpela M, Vuolteenaho K, et al. Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondylarthropathies in clinical practice: Adverse events and other reasons leading to discontinuation of the treatment. Rheumatol Int. 2008;28:261-269.
3. Balog A, Klausz G, Gál J, et al. Investigation of the prognostic value of TNF-> gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-> production and apoptosis. Pathobiology. 2004;71:274-280.
4. Coury F, Ferraro-Peyret C, Le Cam S, et al. Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by antiYtumour necrosis factor alpha therapy. Clin Exp Rheumatol. 2008;26:234-239.
5. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005;21:251-258.
6. Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept. Rheumatology. 2008;47:376-377.
7. Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving antiYtumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010;62:764-769.
8. Catrina AI, Trolimo C, Klint E, et al. Evidence that antiYtumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints. Extended report. Arthritis Rheum. 2005;52:61-72.
9. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2010 69 88-96.
10. Nakamura I, Omata Y, Naito M, et al. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J Rheumatol. 2009;36:459-460.
11. Papadaki HA, Kritikos HD, Valatas V, et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: Improvement following antiYtumor necrosis factor-< therapy. Blood. 2002;100:474-482.
12. Ebert EC, Das KM, Mehta V, et al. Non-response to infliximab may be due to innate neutralizing antiYtumour necrosis factor-< antibodies. Clin Exp Immunol. 2008;154:325-331.